Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Musk's Ex-Girlfriend Interaction Drives Meme Coin PsyopAnime Market Cap Back to $10 Million, Whale Wallet Acquires 9.4 Million Tokens

Musk's Ex-Girlfriend Interaction Drives Meme Coin PsyopAnime Market Cap Back to $10 Million, Whale Wallet Acquires 9.4 Million Tokens

BlockBeatsBlockBeats2026/01/23 05:19

BlockBeats News, January 23rd, according to GMGN monitoring, the market value of Solana-based Meme coin PsyopAnime initiated a rise from today's low point of about $5 million to a peak of $13 million, with a cumulative intraday increase of 140%, currently falling to around $9.6 million, priced at $0.0096.


It is reported that this round of price increase may be mainly due to X's well-known Canadian singer and Elon Musk's former girlfriend Grimes (X: Grimezsz) replying to PsyopAnime's official account yesterday, indicating a discussion on Friday, which triggered the first round of price increase of this Meme coin in the early morning today. At 9 am today, Grimes responded to the latest update from PsyopAnime, stating that she had received the message but had not delved into it yet due to being "very busy" recently.


According to GMGN monitoring, the second round of price increase originated from a trader with a qqP3 starting address, who made a large purchase of 9.41 million tokens at 9:32 am, equivalent to $95,000, briefly driving the token price to $0.0135. This address is the largest buyer in the past 24 hours, with an average holding price of $0.0101.


This Meme coin is based on the X platform account PsyopAnime, which uses AI-generated anime shorts to interpret global news and current hot topics. On January 13th, influenced by Musk's attention to the PsyopAnime official account on the X platform, the Solana-based Meme coin of the same name surged over 3600% within three hours, reaching a peak market value of $27 million.


BlockBeats reminds users that Meme coin trading is highly volatile, heavily reliant on market sentiment and concept hype, with no actual value or use case. Investors should be aware of the risks.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

路透社•2026/10/09 04:26
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low

UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.

智通财经•2026/10/09 03:53